{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-057171","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.688434+00:00","generated_at":"2026-05-14T21:50:18.153586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NextCure reports Q1 net loss $9.8M; cash $29.7M; SIM0505 Fast Track & ASCO data in June","bullets":["Cash and equivalents $29.7M at March 31, 2026, down $12.1M from year-end; runway into H1 2027 through proof-of-concept for SIM0505.","Net loss $9.8M (vs $11.0M YoY); R&D $6.8M, G&A $3.3M, both down vs prior year.","SIM0505 (CDH6 ADC) granted FDA Fast Track for platinum-resistant ovarian cancer; Phase 1 dose optimization initiated May 2026.","Initial Phase 1 dose escalation data for SIM0505 to be presented at ASCO 2026 on June 1, 2026, including US and China patients.","LNCB74 (B7-H4 ADC) Phase 1 dose escalation enrollment ongoing; trial progress update expected in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057171","json":"https://secwatch.observer/filing/0001104659-26-057171.json","markdown":"https://secwatch.observer/filing/0001104659-26-057171.md","text":"https://secwatch.observer/filing/0001104659-26-057171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926057171/0001104659-26-057171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926057171/nxtc-20260507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:50:18.153586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}